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A nonpeptide oxytocin Receptor 
Agonist for a Durable Relief of 
Inflammatory Pain
Louis Hilfiger1, Qian Zhao2, Damien Kerspern1, perrine Inquimbert  1, Virginie Andry1, 
Yannick Goumon1, pascal Darbon1, Marcel Hibert2 & Alexandre charlet  1*
Oxytocin possesses several physiological and social functions, among which an important analgesic 
effect. For this purpose, oxytocin binds mainly to its unique receptor, both in the central nervous system 
and in the peripheral nociceptive terminal axon in the skin. However, despite its interesting analgesic 
properties and its current use in clinics to facilitate labor, oxytocin is not used in pain treatment. 
Indeed, it is rapidly metabolized, with a half-life in the blood circulation estimated at five minutes and 
in cerebrospinal fluid around twenty minutes in humans and rats. Moreover, oxytocin itself suffers from 
several additional drawbacks: a lack of specificity, an extremely poor oral absorption and distribution, 
and finally, a lack of patentability. Recently, a first non-peptide full agonist of oxytocin receptor 
(LIT-001) of low molecular weight has been synthesized with reported beneficial effect for social 
interactions after peripheral administration. In the present study, we report that a single intraperitoneal 
administration of LIT-001 in a rat model induces a long-lasting reduction in inflammatory pain-induced 
hyperalgesia symptoms, paving the way to an original drug development strategy for pain treatment.
Oxytocin (OT) is a 9–amino acid neuropeptide that plays an important role in several physiological and social 
functions. It was discovered by Sir Henry Dale for its role in lactation and parturition1. In the brain, OT is mainly 
synthesized in the paraventricular and supraoptic nuclei of the hypothalamus and released into the bloodstream 
by the neurons of the pituitary gland2. OT binds mainly to its unique receptor (OTR), a member of the G-protein 
coupled receptor (GPCRs) family. Its amino acid sequence was elucidated in 19533 and its receptor gene was 
isolated in 19924.



OT has been shown to induce antinociception as well as analgesia5. The antinociceptive and analgesic effects 
after intrathecal or systemic administration of OT are well-documented6–8. For instance, OT has a dose depend-
ent analgesic effect in a rat model of inflammatory pain8, and Petersson et al. have shown that OT was also able 
to reduce the size and volume of the inflammation7. In addition, one study proposed that OT can also bind OTR 
directly in the peripheral nociceptive terminal axon in the skin9.
Interestingly, in nociception and pain, OT has central and peripheral targets depending on the releasing path-
way: plasmatic released OT has in vivo antinociceptive action through reduction of C fiber excitability leading to a 
reduction of activity of wide dynamic range (WDR) spinal sensory neurons10 whereas OT released by fibers orig-
inating from PVN directly on WDR neurons inhibits sensory processing and produces analgesia in inflammatory 
pain model11,12. In these models, direct activation of parvocellular OT neuron by optogenetics, resulting in central 
and peripheral release of endogenous OT, also produced a significant OTR-dependent analgesia11.
In clinics, OT is used since many years in patients by the intravenous route for the initiation of labor and 
the final expulsion of the fetus13. It is also administered to women as a nasal spray to stimulate milk ejection. 
However, despite its interesting analgesic properties, OT is not used in pain treatment because it cannot efficiently 
penetrate the brain14 and is rapidly metabolized. OT half-life in the blood circulation is estimated at 5 minutes in 
humans and rats15 and around 20 minutes in rat cerebrospinal fluid (CSF)16. Moreover, OT suffers from several 
additional drawbacks: a lack of specificity, since this cyclic nonapeptide has very similar affinities for its receptor 
OTR, for the V1a vasopressin receptor (V1aR)17,18 and for the Transient Receptor Potential Vanilloid type-1 
(TRPV1) of the capsaicin (EC50 = 0.316 μM)19; an extremely poor oral absorption and distribution since its high 
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molecular weight prevents or strongly limits its absorption from the gastro intestinal tract to the blood or from 
the blood to the brain; and finally, a lack of patentability.
Recently, a first non-peptide full agonist of oxytocin (LIT-001) has been reported to improve social interac-
tions in a mouse model of autism after peripheral administration20. LIT-001 is a pyrazolobenzodiazepine deriva-
tive with a non-peptide chemical structure and a low molecular weight (MW) compared to oxytocin (MW = 531 
vs. 1007, respectively, Fig. 1a). Frantz et al. have shown that LIT-001 is a specific oxytocin receptor agonist with 
high affinity (EC50 = 25 nM and EC50 = 18 nM) and efficacy (Emax = 96% and 95%) for human and mouse recep-
tors, respectively. Furthermore, the compound poorly antagonized vasopressin induced calcium release on V1aR 
(IC50 = 5900 nM) and was devoid of agonist or antagonist effect on V1b-R.
In the present study, we report that a single intraperitoneal administration of LIT-001 in a rat model induces a 
long-lasting reduction in inflammatory pain-induced hyperalgesia symptoms, paving the way to an original drug 
development strategy for pain treatment.
Results
LIT-001, a non-peptidergic oxytocin receptor agonist. The thermodynamic water solubility (S) of 
LIT-001 was measured in PBS buffer at pH 7.4: S = 0.53 ± 0.03 mM (0.34 mg/mL). Its lipophilicity in the same 
conditions was experimentally determined: LogD7.4 = 2.0 ± 0.3 (Fig. 1a). The selectivity of LIT-001 (at 5 μM) has 
been tested on classical off-targets: 24 G-protein-coupled receptors (GPCRs), 3 transporters, 10 enzymes and 6 
ion channels. No significant agonist or antagonist (Fig. 1b) activity was found at GPCRs levels or at the ionotropic 
TRPV1 receptor. Similarly, no significant uptake blockade is observed on noradrenaline, dopamine and serotonin 
transporters from rat brain synaptosomes (Fig. 1c). In addition, no enzyme inhibition activity was found on the 
human recombinant COX(1), PDE3A, Lck kinase, acetylcholinesterase and MAO-A from human placenta (6.4% 
to 9.5% inhibition, below significance) (Fig. 1c). Some inhibitory activity of COX(2) and PDE4D2 was however 
observed (24.6 and 23.1% at 5 μM, respectively) (Fig. 1c). On ion channels, no significant blockade activity was 
found on human hERG potassium, GABAA (alpha1/beta2/gamma2), Cav1.2 (L-type) calcium, Vav1.5 sodium, 
nAChR (alpha4/beta2) and KCNQ1/hminK potassium ion channels (Fig. S1). Finally, the lack of hERG inhibition 
was confirmed at two additional concentrations using patch clamp method (9.50% and 10.63% inhibition at 1 μM 
and 10 μM concentrations, respectively). In vitro, LIT-001 did not interact with CYP 2C9 and 2D6 cytochromes 
and weakly inhibited CYP 1A2, 2C19 and 3A4 (IC50 = 51, 21 and 11 μM, respectively). Interesting, tested at 1 μM, 
LIT-001 was very stable on human hepatocytes at 37 °C since no degradation was observed after 2 hours.
Altogether, these results indicates that LIT-001 is a very specific agonist for OTR, with limited off-targets 
and putative side-effects, and a long lasting (>2 h) half-life; all characteristics requested for a clinically-relevant 
compound.
Ten days’ time course of long-term modifications induced by CFA subcutaneous injec-
tion. Before testing the putative analgesic action of LIT-001, we started by characterizing the long-term mod-
ifications induced by a single subcutaneous injection of complete Freund adjuvant (CFA, 100 μl) in the right 
hindpaw (Fig. 2a). We first measured the hindpaw diameter and observed that CFA, but not NaCl 0.9%, injection 
induced a major edema, whose size was maximum 24 h after the injection (CFA: 9.69 ± 0.22 mm, n = 14 vs NaCl: 
5.73 ± 0.14 mm, n = 11; p < 0.01) and persistent for up to 10 days (Fig. 2b). On the other hand, the mechanical 
CFA-induced hyperalgesia was maximum 24 h after the injection (threshold pressure CFA: 122 ± 15 g, n = 14 vs 
NaCl: 520 ± 14 g, n = 18; p < 0.01) and, as the edema, was persistent up to 10 days (Fig. 2c1). Similarly, a thermal 
heat hyperalgesia was detected for up to 10 days and maximum 24 h after the CFA injection (withdrawal latency 
CFA: 2.5 ± 0.23 s, n = 14 vs NaCl: 10.31 ± 0.38 s, n = 18; p < 0.01; Fig. 2c2). Interestingly, the contralateral hind-
paw to the CFA-injected one did not present any mechanical nor thermal heat hypersensitivity (Fig. S2). Based on 
these results, we decided to test the putative analgesic properties of LIT-001 at 24 h (D1) after the CFA injection.
Analgesic properties of LIT-001 on CFA-induced inflammatory pain model. We next aimed to test 
the putative analgesic properties of LIT-001 in the CFA-induced inflammatory pain model. For this purpose, we 
first performed a dose-response of the analgesic action of LIT-001 injected intraperitoneally (i.p.) at day 1 (D1) 
after the CFA injection, when the inflammatory pain symptoms were at their maximum (Fig. 3). We found a first 
analgesic action of i.p. LIT-001 at 5 mg/kg, an effect rising to reach a plateau at 10 mg/kg, that for both mechani-
cal (Fig. 3a) and thermal heat (Fig. 3b) hypersensitivities. Importantly, none of the doses tested seem to exert an 
antinociceptive action, as measured on the contralateral hindpaw (Fig. S3).
Therefore, performed a time-course of the analgesic effect of i.p. LIT-001 (10 mg/kg) injected at day 1 (D1) 
after the CFA injection (Fig. 4a). For that purpose, we analyzed the hindpaw size as well as the mechanical and 
thermal heat hypersensitivities for 24 h (Fig. 4b–d).
We first found that i.p. LIT-001, injected alone or with a specific oxytocin receptor antagonist, L-368,699 
(L-368), had no effect on the CFA-induced edema size (CFA + Vehicle, 9.44 ± 0.18 mm, n = 7; CFA + LIT-001, 
9.49 ± 0.23 mm, n = 8; CFA + LIT-001 + L-368, 10.32 ± 0.17 mm, n = 7; Fig. 4b). This suggests that acute LIT-001 
injection, at this stage of the CFA-induced inflammation, may have no or limited anti-inflammatory effect per se.
However, we revealed that i.p. LIT-001 exert an anti-hyperalgesic action on mechanical threshold (Fig. 4c1). 
This effect was significant from 1 to 5 h after i.p. injection, with a maximal effect at 3 h (CFA + Vehicle, 126 ± 29 g, 
n = 7 vs CFA + LIT-001, 246 ± 22 g, n = 8; p < 0.001), as reflected by an increase of the area under the curve 
(AUC) of 152 ± 11%. We observed a similar anti-hyperalgesic action on thermal heat latency (Fig. 4c2), sig-
nificant from 1 to 5 h after i.p. injection, with a maximal effect at 3 h (CFA + Vehicle, 1.94 ± 0.18 s, n = 7 vs 
CFA + LIT-001, 5.83 ± 0.65 s, n = 8; p < 0.001), as reflected by an increase of the AUC of 135 ± 9%. These results 
indicate that i.p. LIT-001 exerts a strong significant and long-lasting anti-hyperalgesic action on both mechanical 
and thermal heat sensitivities.
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Figure 1. Pharmacological functional profile of LIT-001 on off-targets. (a) LIT-001 structure, physico-chemical 
properties and potency on target receptors. (b) In vitro agonist and antagonist profiles of LIT-001 on 24 off-
target GPCRs. Cellular agonist and antagonist effects of LIT-001 were calculated as a % of control response to 
a known reference agonist for each target and cellular antagonist. Negative values are non significant in these 
assay setups. (c) Enzyme and transporter inhibition potency of LIT-001 on selected off-targets. Compound 
enzyme inhibition effect was calculated as a % inhibition of control enzyme activity. Compound uptake 
inhibition effect was calculated as a % inhibition of control uptake activity. Data are expressed as the mean value 
of 2 independent tests.
Un
co
rre
cte
d p
roo
f
4Scientific RepoRtS | _#####################_ | https://doi.org/10.1038/s41598-020-59929-w
www.nature.com/scientificreportswww.nature.com/scientificreports/
Given that LIT-001 was built as a specific agonist for OTR, we thought to validate that these anti-hyperalgesic 
effects were mediated by OTR activation. For this purpose, we co-injected LIT-001 with a specific OTR antag-
onist, L-368,69911. As expected, the anti-hyperalgesic action of i.p. LIT-001 was fully prevented by L-368,699, 
as displayed by the mechanical threshold (CFA + LIT-001 + L-368, 119 ± 12 g, n = 7) and thermal heat latency 
(CFA + LIT-001 + L-368, 3.08 ± 0.29 s, n = 7) and their relative AUC (90 ± 7% and 92 ± 8%, respectively) values 
3 h post i.p. (Fig. 4c). These results indicate that i.p. LIT-001 likely exerts its anti-hyperalgesic action through OTR 
binding.
One important point in the development of a clinically-relevant anti-hyperalgesic compound is the limitation 
of its side effect, here the absence of anti-nociception. Noteworthy, we did not detect any alteration of contralat-
eral hindpaw sensitivities after i.p. LIT-001, being on mechanical threshold (cCFA + LIT-001, 531 ± 25 g, n = 8; 
Fig. S4a1) or thermal heat latency (cCFA + LIT-001, 11 ± 0.53 s, n = 8; Fig. S4a2). Interestingly, we made similar 
observation on control animals, receiving NaCl 0.9% hindpaw injection and thus not presenting inflammatory 
pain symptoms (Figs. 4d, S4b). Here, i.p. LIT-001, injected alone or co-injected with the specific oxytocin receptor 
antagonist L-368,699, had no effect on mechanical (NaCl + LIT-001, 526 ± 20 g, n = 7; Figs. 4d1, S4b1) or thermal 
heat (NaCl + LIT-001, 8.14 ± 0.48 s, n = 7; Figs. 4d2, S4b2) hindpaw sensitivities, as reflected by the absence of 
increase of the AUC (Figs. 4d, S4b). These results indicate that i.p. LIT-001, as an analgesic, is only effective in case 
of detectable hypersensitivities.
LIT-001 distribution and clearance in the organism. Because the anti-hyperalgesic effects of i.p. LIT-
001 10 mg/kg were long-lasting, up to 5 h, while oxytocin-induced analgesia usually only last for minutes, we 
analyzed its distribution at key time points in plasma, CSF, brain and urine (n = 5–6, Fig. 5) and performed a 
quantitative dosage by comparison to a dose-response curve, using Liquid Chromatography Mass Spectrometry 
(LC-MS/MS; Fig. S5). Interestingly, LIT-001 concentration was found in plasma at its highest 30 min after i.p. 
injection (650 ± 200 pmole/ml; Fig. 5b) then slowly decreased, but was still significantly present after 300 min 
(5 h; 95.2 ± 36.5 pmole/ml; Fig. 5b,c). In addition, LIT-001 was found in significant amount in both the brain and 
CSF 60 min after i.p. injection (1.6 ± 0.8 and 7.4 ± 4.4 pmole/ml, respectively; Fig. 5c) when its analgesic action 
is significantly observed. As expected according to its chemical structure and previous half-life evaluation, after 
5 h most of LIT-001 was found in urine (188951 ± 8475 pmole/ml; Fig. 5c) and was hardly detectable in both 
CSF (1.5 ± 1.1 pmole/ml) and brain (0.6 ± 0.4 pmole/mL; Fig. 5c). These results indicate that the long-lasting 
Figure 2. Ten days’ time course of long-term modifications induced by CFA subcutaneous injection.  
(a) Scheme of the CFA-induced inflammatory pain model (100 μl). (b) Time-course of the CFA-induced edema 
size (CFA, n = 14; NaCl, n = 18). (c) Time-course of the CFA-induced mechanical (c1) and thermal heat  
(c2) hyperalgesia (CFA, n = 14; NaCl, n = 18). Data are expressed as mean ± SEM. Asterisks indicate statistical 
significance (***p < 0.001) using two-way ANOVA followed by Tukey multiple comparisons post-hoc test.
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anti-hyperalgesic effect of i.p. LIT-001 is likely due to its prolonged presence in plasma, with putative central 
effects.
Discussion
In the present study, we show that LIT-001, a non-peptidergic specific agonist for OTR, exerts a significant 
long-lasting (>5 h) anti-hyperalgesic effect on both mechanical and thermal heat sensitivity.
Antinociceptive and analgesic action of OT is well documented21–23. It has been shown to act at both 
peripheric and central levels10 mainly through final reduction of spinal wide dynamic range (WDR) neurons and 
C fiber excitability11. However, the main limitations of OT, or OTR peptidergic agonists, are (i) the short duration 
of the effect, (ii) the lack of permeability through the blood brain barrier (BBB), and (iii) the lack of specificity, 
which all are not compatible with clinical use.
Here, we show that a low molecular weight, non-peptidergic agonist, LIT-001, exerts a long lasting antihy-
peralgesic effect, up to 5 h. Two points may explain the prolonged effect of LIT-001. First, it has a long half-life 
(>2 h), by comparison to OT or OTR peptidergic agonists, which all have a very short half-life of less than 15 min. 
Second, it may reach its central and/or peripheral targets and trigger here long lasting mechanisms involving 
OTR. At this point, it is important to highlight that, for clinical purpose and mainly in case of chronic pain, a 
strong analgesic candidate should not only focus on nociception but also positively modulate all pain-induced 
disorders, such as anxiety, depression, loss of social interaction, impaired food intake or stress. Indeed, to atten-
uate this large variety of pain-relative symptoms may significantly improve the patient quality of life, one of the 
main goals of modern medicine. In this regard, to target the oxytocinergic system, in particular with specific 
OTR agonist such as LIT-001, may be particularly relevant. Indeed, activation of OTR is known to induce a 
variety of molecular cascades24 resulting in an important modulation of nociception25, social recognition and 
interactions26,27, anxiety28, feeding behavior29, and stress30, all important comorbidity factors in painful patients. 
Figure 3. Dose-response of the analgesic properties of LIT-001 on CFA-induced inflammatory pain model. 
Effects of LIT-001 0.1 (n = 4), 1 (n = 6), 5 (n = 6), 10 (n = 8) and 15 mg/kg (n = 6) or its vehicule (n = 9) 
measured 1 hour after i.p. injection on mechanical (a) and thermal heat (b) CFA-induced hyperalgesia. Data 
are expressed as mean ± SEM. Asterisks indicate statistical significance (**p < 0.01; *p < 0.05) using paired 
Wilcoxon or T-test, depending on the data’s normal distribution.
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Interestingly, a previous study has also shown that LIT-001 improved social interaction in a mouse model of 
autism20, reinforcing its putative interest as an analgesic molecule.
Besides, we confirm the capability of LIT-001 to cross the blood brain barrier to exert its action in the cen-
tral nervous system20 (Fig. 5). In addition, we show that LIT-001 exerts long lasting anti-hyperalgesic effects. 
Importantly, LIT-001 does not accumulate in the body but is almost entirely excreted as such in the urine. While 
those data were obtained by intra-peritoneal injection, we hypothesize that similar results may be obtained using 
an oral administration of LIT-001. If true and transposable to man, it may lead to the development of a drug easy 
to take every few hours to limit pain symptoms. Those aspects point toward LIT-001, and future non-peptidergic 
agonists, as key candidates for clinical use. Although it displays a low micromolar affinity for this receptor, LIT-
001 is a potent V2R agonist in functional assays20, The V2 receptor is peripheral and known to regulate water 
homeostasis. It is thus likely that LIT-001 will have some antidiuretic effect in vivo that will have to be studied and 
taken into account for a potential development toward clinical studies.
Because of its long half-life and its capability to cross the BBB, one may worried about the putative LIT-
001 side effects: to design drugs with limited side-effects is a major challenge in chemical and pharmaceutical 
industries. Importantly, LIT-001 does not interact significantly with any classical off targets (G protein coupled 
Figure 4. Time-course of the analgesic properties of LIT-001 on CFA-induced inflammatory pain model.  
(a) Scheme of the CFA-induced inflammatory pain model followed by i.p. LIT-001 injection. (b) Left, time-
course of the effects of i.p. LIT-001 10 mg/kg (n = 8), its vehicule (n = 7) or co-injection with L-368,699 (n = 7), 
on CFA-induced edema size (CFA, n = 14; NaCl, n = 18). Right, relative-to-baseline AUC (%) of the effects. 
(c) Left, time-course of the effects of i.p. LIT-001 10 mg/kg (n = 7), its vehicule (n = 8) or co-injection with 
L-368,699 (n = 6) on CFA-induced mechanical (c1) and thermal heat (c2) hyperalgesia. Right, relative-to-
baseline AUC (%) of the effects. (d) Left, time-course of the effects of i.p. LIT-001 10 mg/kg (n = 7), its vehicule 
(n = 8) or co-injection with L-368,699 (n = 6) on mechanical (d1) and thermal heat (d2) sensitivities of  
NaCl-injected hindpaw. Right, relative-to-baseline AUC (%) of the effects. Data are expressed as mean ± SEM. 
Asterisks indicate statistical significance (***p < 0.001; **p < 0.01; *p < 0.05) using two-way ANOVA followed 
by Tukey’s multiple comparisons test.
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receptors, transporters, enzymes, ion channels listed in Figs. 1, S1), neither as an agonist/activator nor an antago-
nist/inhibitor. Noteworthy, neither LIT-001 nor the OT antagonist L-368,699 displayed any significant agonist or 
antagonist activity at the TRPV1 receptor at 5 μM (Fig. 1b). Therefore, LIT-001 is a relatively specific OTR agonist 
likely exerting its analgesic effect via this receptor. This conclusion is strengthened by our results showing that the 
LIT-001 antihyperalgesic action is fully prevented in presence of L-368,699, a specific OTR antagonist that is also 
devoid of significant activity at TRPV1 receptor at 5 μM. In addition, an interesting aspect of LIT-001 seems to 
be its specific action on nociception and pain. Indeed, while LIT-001 shows limited inhibitory activity of COX2, 
which in a model of inflammatory pain could be relevant, we observed no modification of the size of the edema 
induced by CFA injection (Fig. 4), indicating that the LIT-001-induced reduction of pain symptoms is not based 
on a reduction of inflammation. However, we did not rule specific protocols to tests its anti-inflammatory action 
per se, and this should be done before any clinical trial. In addition, it is important to note that LIT-001 did not 
modify the mechanical/thermal heat sensitivities in control animals or contralateral paws, indicating that LIT-
001 does not have antinociceptive effect, which, in a clinical perspective, is an important characteristic in order 
to limit undesired loss of sensitivities. At this stage, the only known drawback of LIT-001 is its action at the V2 
vasopressin receptor (V2R).
In conclusion, we found that LIT-001 is a very useful probe to validate the oxytocin receptor as a target for the 
treatment of pain and represents a promising drug-like lead compound for the development of novel treatments.
Methods
All the protocols, tests and use and living animals were performed in accordance with European committee 
council Direction, authorization from French Department of Agriculture and from the regional ethic committee 
(Comité Régional d’Ethique en Matière d’Expérimentation Animale de Strasbourg, CREMEAS).
Drugs. LIT-001 was prepared as described in Frantz et al.20. For in vivo biological assays, it was dissolved in 
carboxymethyl cellulose (CMC, 1%) - NaCl (0.9%) and administered at the dose of 10 mg/kg. LIT-001 or vehicle 
were injected intraperitoneally (i.p.), in a volume of 10 ml/kg20, 24 h after the induction of the CFA-induced pain-
ful inflammatory sensitization. To confirm the implication of the OTR we injected (i.p.) also L-368,899 (Sigma, St. 
Louis, MO) (1 mg/kg), an OTR antagonist, in combination with LIT-001 in another group of rats11.
In vitro physicochemical and pharmacological characterization. Solubility of LIT-001 was deter-
mined from solution of about 1 mg of compound in 500 μl of PBS at pH 7.4. (Figs. 1, S1) The solution was stirred 
at room temperature for

 24 h and centrifuged at 15.000 × g for 5 min. The supernatant was diluted with a mix-
ture of acetonitrile and water and analyzed by HPLC with a diode detector (Gilson; Kinetex 2.6 μm C18 100 A 
50 × 4.6 mm column). No degradation of LIT-001 was observed after 24 h. The lipophilicity (LogD7.4) of LIT-001 
was measured using 10 ml of a stock solution diluted with different concentrations of octanol and PBS to cover 
a LogP range from −2 to + 4.5 in a final volume of 1 ml. After stirring for 1 h at room temperature (≈ 20 °C), the 
Q5
Figure 5. LIT-001 distribution and clearance in the organism. (a) Scheme displaying the i.p. injection of 
LIT-001, 10 mg/kg in naïve animal. (b) Time course of the concentrations of LIT-001 present in the plasma of 
rats after an i.p. Injection. (c) Concentrations of LIT-001 present at 60 and 300 min after i.p. injection, in the 
brain (60, n = 6; 300, n = 5), CSF (60, n = 4; 300, n = 4), plasma (60, n = 11; 300, n = 5) and urine (60, n = 6; 
300, n = 5) 60 min and 300 min after i.p. Injection. Data are expressed as mean ± SEM. Data are expressed as 
mean ± SEM of 5 animals.
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samples were centrifuged and the different phases were analyzed by HPLC (Gilson; diode detector, Kinetex 2.6 μ 
C18 100 A 50 × 4.6 mm column).
Stability of LIT-001 was determined in human hepatocytes. Cells were unfrozen and their viability measured 
(Tryptan blue). Cells are suspended (2 × 106 cells/ml) and dispensed in 96 well microtiterplates (50 μL/well). 
LIT-001 (50μL of a 2μM in the incubation media) was added. The final concentration of the compound was 1 μM 
in 1 × 106 cells/ml. The incubation volume was 100 μl/well. Incubations were stopped after 0, 4, 20, 40, 80 and 
120 min in mixing the well content with 100 μl acetonitrile at 0 °C. A positive control (testosterone) was prepared 
in same conditions. All samples were analyzed by LC-MS/MS (UHPLC coupled to a triple quadripole Shimadzu 
LC-MS 8030). Each measurement was performed in triplicate.
In vitro profiling of LIT-001 was performed by Eurofins as described in the Eurofins SafetyScreen-Functional 
panel, 201831. The hepatotoxicity of LIT-001 was studied with cryo-preserved mouse hepatocytes. After unfreez-
ing (optiTHAW and optiINCUBATE media, Xenotech) and cell viability control, cells (2 × 106 cells/ml) were dis-
patched in 96 well microtiterplates. LIT-001 was added to reach a concentration 1 μM in the presence of 1 × 106 
cells/mL in a volume of 100 μl/well. The incubation was stopped at 4, 20, 40, 80 and 120 min in adding 100 μl of 
acetonitrile at 0 °C. A positive control was treated in the same conditions. All samples were analyzed by UHPLC 
coupled to a mass spectrometer (Shimadzu LC-MS 8030).
Cytochrome inhibition by LIT-001 was studied as follows. A stock solution of LIT-001 at 10 mM in DMSO 
was prepared and stored at 4 °C. Solutions containing the cytochrome substrates and control inhibitors or LIT-
001 were prepared. 2 μl of substrate-inhibitor solutions were mixed with 176 μl of phosphate buffer containing 
human liver microsomes (0.2 mg/ml), 1 mM of NADPH and 3 mM of MgCl2. Height concentrations were tested: 
0.03; 0.1; 0.3; 1; 3; 10; 30 and 100 μM. The reaction was initiated by addition of the co-factor after 5 min of incu-
bation at 37 °C. After one hour of incubation, 200 μl of acetonitrile were added to stop enzymatic reactions and 
solubilize the products. Different control inhibitors were used and supernatants were analyzed by LC-MS/MS 
(UHPLC separation; Shimadzu LC-MS 8030).
•	 Furafylline (CYP 1A2 inhibitor): 0.03; 0.1; 0.3; 1; 3; 10; 30 and 100 μM
•	 Sulfaphenazole (CYP 2C9 inhibitor): 0.03; 0.1; 0.3; 1; 3; 10; 30 and 100 μM
•	 Tranylcypromine (CYP 2C19 inhibitor): 0.03; 0.1; 0.3; 1; 3; 10; 30 and 100 μM
•	 Quinidine (CYP 2C19 inhibitor): 0.003; 0.01; 0.1; 0.5; 1; 5; 10 and 50 μM
•	 Kétoconazole (CYP 3A4 inhibitor): 0.003; 0.01; 0.1; 0.5; 1; 5; 10 and 50 μM
Animals. Male Wistar rats (300 g; JANVIER LABS, Le Genest St. Isle, France) were used for this study. They 
were housed by groups of 3 or 4 under standard conditions (room temperature, 22 °C; 12/12 h light/dark cycle) 
with ad libitum access to food and water and behavioral enrichment. All animals were manipulated and habitu-
ated to the tests and to the room for at least 2 weeks. All behavioral tests were done during the light period (i.e., 
between 7:00 and 19:00). All the procedures were performed in accordance with European committee council 
Direction, authorization from French Department of Agriculture and from the regional ethic committee.
Behavioral testing. Mechanical allodynia. In all experimentations, to test the animal mechanical sensi-
tivity, we used a calibrated forceps (Bioseb, Chaville, France) previously developed in our laboratory (Figs. 2, 3 
and S2, S3)32. Briefly, the habituated rat is loosely restrained with a towel masking the eyes in order to limit stress 
by environmental stimulations. The tips of the forceps are placed at each side of the paw and a graduate force is 
applied. The pressure producing a withdrawal of the paw, or in some rare cases a vocalization of the animal, cor-
responded t  the nociceptive threshold value. This manipulation was performed three times for each hindpaw 
and the values were averaged
Thermal allodynia/hyperalgesia. To test the animal heat sensitivity, we used the Plantar test with Hargreaves 
method (Ugo Basile, Comerio, Italy) to compare the response of each hindpaw33 when we tested healthy ani-
mals (unilateral intraplantar NaCl injection) and animals having received unilateral intraplantar CFA (Freund’s 
Complete Adjuvant) injection. The habituated rat is placed in a small box and we wait until the animal is calmed 
then we exposed the hindpaw to a radiant heat, the latency time of paw withdrawal was measured.
CFA model of inflammatory pain. In order to induce a peripheral inflammation, 100 μl of complete Freund adju-
vant (CFA; Sigma, St. Louis, MO), was injected in the right hindpaw of the rat. All CFA injections were performed 
under light isoflurane anesthesia (3%). Animals were tested daily for 10 days after the paw injection, a period 
during which animals exhibited a clear mechanical allodynia and thermal heat hyperalgesia.
Pharmacokinetics of LIT-001. Preparation of brain, cerebrospinal fluid, plasma and urine extracts. Brains 
from rat injected with 10 mg/kg (18.8 µmol/kg) i.p. of LIT-001 were homogenized with an Ultra Turrax instru-
ment (Ika, Staufen, Germany) in 2 ml of H2O (Figs. 4, S4). The homogenates were then sonicated (3 times 10 s, 
100 W) with a Vibra Cell apparatus (Sonics, Newtown, U.S.A.). Protein concentrations were determined using the 
Bradford method (Protein Assay, Bio-Rad, Marne-la-Coquette, France). 400 µl was mixed with 4 ml of ice cold 
acetonitrile (ACN) and let 30 min on ice. Samples were then centrifuged (20,000 × g, 30 min) at 4 °C. Supernatants 
were dried under vacuum and resuspended in 400 µl ACN 10%/H2O 89.9%/formic acid 0.1% (v/v/v) and a vol-
ume of 5 µl was injected on the LC-MS/MS. For CSF, plasma and urine, 200 µl of fluids were mixed with 1 ml of 
ice cold acetonitrile (ACN) and let 30 min on ice. Samples were then centrifuged (20,000 × g, 30 min) at 4 °C. 
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Supernatants were dried under vacuum and suspended in 200 µl ACN 10%/H2O 89.9%/formic acid 0.1% (v/v/v) 
and a volume of 5 µl was injected on the LC-MS/MS.
LC-MS/MS instrumentation and analytical conditions. Analyses were performed on a Dionex Ultimate 3000 
HPLC system (Thermo Scientific, San Jose, USA) coupled with a triple quadrupole Endura mass spectrome-
ter (Thermo Scientific). The system was controlled by Xcalibur v.2.0 software (Thermo Electron). Samples were 
loaded onto an Accucore C18 RP-MS column (ref 17126–151030; 150 × 1 mm 2.6 μm, Thermo Scientific) heated 
at 40 °C. The presence of LIT-001 was studied using the multiple reaction monitoring mode (MRM). Elution 
was performed at a flow rate of 150 µl/min by applying a linear gradient of mobile phases A/B. Mobile phase A 
corresponded to ACN 1%/H2O 98.9%/formic acid 0.1% (v/v/v), whereas mobile phase B was ACN 99.9%/formic 
acid 0.1% (v/v). The gradient used is detailed in Fig. S4. Electrospray ionization was achieved in the positive mode 
with the spray voltage set at 3,500 V. Nitrogen was used as the nebulizer gas and the ionization source was heated 
to 210 °C. Desolvation (nitrogen) sheath gas was set to 27 Arb and Aux gas was set to 9 Arb. The ion transfer tube 
was heated at 312 °C. Q1 and Q2 resolutions were set at 0.7 FWHM, whereas collision gas (CID, argon) was set to 
2 mTorr. Identification of the compounds was based on precursor ion, selective fragment ions and retention times 
obtained for LIT-001. Selection of the monitored transitions and optimization of collision energy and RF Lens 
parameters were manually determined (see Fig. S4 for details). Qualification and quantification were performed 
in MRM mode. Quantification was obtained using Quan Browser software (Thermo Scientific). For tissues and 
fluids, LIT-001 was quantified using calibration curves of external standards of LIT-001 (125 fmol to 100 pmol/
injection; Fig. S4) added to urine, plasma or brain extracts of naive rat and submitted to the same procedure 
described for respective fluids and tissue recovery. The amounts of LIT-001 measured in samples fit within the 
standard curve limits, with typical analytical ranges (the range of amounts that can be accurately quantified) from 
150 fmol to 120 pmol.
Statistical analysis. Data are expressed as mean ± standard error of the mean (SEM). Statistical tests were 
performed with GraphPad Prism 7.05 (GraphPas Software, San Diego, California, USA) using repeated-measures 
two-way ANOVA, with the following factors: treatment (between), and time (within); when the ANOVA test was 
significant, the Tukey test was used for post-hoc multiple comparisons between individual groups. Results were 
considered to be statistically significant if p values were below 0.05 (*), 0.01 (**), and 0.001 (***). For the area 
under the curve (AUC) comparisons, we used the one-way ANOVA (factors: treatment); when the ANOVA test 
was significant, the Tukey test was used for post hoc multiple comparisons.
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